R41/R42 Small Business Technology Transfer Grant (STTR)
Lead Optimization and Pre-Clinical Development of Therapeutic Candidates for Diseases of Interest to the NIDDK (R41/R42)
The goal of this Funding Opportunity Announcement (FOA) is to support lead optimization and preclinical development of new therapies for diseases within the mission of the NIDDK. Phase I supports preliminary steps in the process for lead optimization or preclinical development of therapeutics. Phase II supports lead optimization and preclinical development of lead candidates and projects must be sufficiently advanced such that an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA) can be submitted by the end of a Phase II or IIB project. Applications are expected to have defined Milestones and Timelines detailing how the project will move forward with identified key Go/No Go decision points.
|Notice(s) for this Opportunity|
|Letter of Intent Due Date|
|Application Due Date|Standard dates
apply, by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.